The Effect of Effervescent Alendronate on Bone Turnover
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
64 postmenopausal women are randomized to treatment with either effervescent and buffered
alendronate or conventional alendronate -both 70mg weekly for 16 weeks to see if bone
turnover is suppressed to the same extent as in the conventional formulation with the
effervescent form.